semaglutide a1c Hemoglobin Reduction With the GLP-1 Receptor Agonist Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs Real-World HbA1c Changes Among Type

In this analysis, a 68-week horizon was chosen to align with available data from the STEP-8 clinical trial [22]

To view or add a comment, sign in #PRESS: PILA PHARMA ENTERS INTO AGREEMENT WITH THE CRO Gubra ON PRECLINICAL TRIALS OF XEN-D0501 IN #OBESITY Link to the news: #PILA #Biotech #Investment #Diabetes #Obesity #TRPV1 To view or add a comment, sign in Its intriguing to see the reintegration of pain signaling pathways into #obesity therapeutics

The article's table says glass vials with rubber septa maintain sterility better than plastic, and that syringes have shorter stability than vials

Zealand Pharma is another important name because of licensing activity around survodutide